Home>>(D-Arg¹,D-Phe⁵,D-Trp⁷·⁹,Leu¹¹)-Substance P

(D-Arg¹,D-Phe⁵,D-Trp⁷·⁹,Leu¹¹)-Substance P

Catalog No.GA20072

(D-Arg¹,D-Phe?,D-Trp?.?,Leu¹¹)-Substance P initially described as a low potency ghrelin receptor antagonist has surprisingly been found to be a full inverse agonist (EC?? = 5.2 nM). In COS-7 cells transiently transfected with the ghrelin receptor the substance P analog rPKPfQwFwLL decreased the constitutive signaling down to levels observed in untransfected cells. Assuming that constitutive signaling of the ghrelin receptor is of physiological relevance in the regulation of appetite control, inverse agonists of the ghrelin receptor could be interesting for the treatment of obesity. So, Asakawa et al. found that peripherally administered H-6395 decreased food intake in lean mice, in mice with diet induced obesity, and in ob/ob obese mice.

Products are for research use only. Not for human use. We do not sell to patients.

(D-Arg¹,D-Phe⁵,D-Trp⁷·⁹,Leu¹¹)-Substance P Chemical Structure

Cas No.: 96736-12-8

Size Price Stock Qty
1mg
$114.00
In stock
5mg
$459.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

(D-Arg¹,D-Phe5,D-Trp7.9,Leu¹¹)-Substance P initially described as a low potency ghrelin receptor antagonist has surprisingly been found to be a full inverse agonist (EC = 5.2 nM). In COS-7 cells transiently transfected with the ghrelin r

Reviews

Review for (D-Arg¹,D-Phe⁵,D-Trp⁷·⁹,Leu¹¹)-Substance P

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (D-Arg¹,D-Phe⁵,D-Trp⁷·⁹,Leu¹¹)-Substance P

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.